SystImmune is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer, founded in 2014 and operating from facilities in Redmond, Washington and Princeton, New Jersey. The company specialises in bispecific antibodies, multi-specific antibodies, and antibody-drug conjugates (ADCs), with multiple assets advancing through clinical trials for solid tumour and haematologic indications alongside a robust preclinical pipeline.
The company operates four proprietary technology platforms: SEBA for bispecific antibody development, HIRE ADC described as the globally leading platform for ADC development, GNC for multi-specific antibody discovery, and AIDP, an AI-powered platform for computational drug design. Its clinical-stage lead programme, BL-B01D1 (iza-bren), an EGFRxHER3 bispecific ADC, is subject to a global strategic collaboration with Bristol Myers Squibb for co-development and co-commercialisation.
The company assembles a team of experienced R&D scientists and biotech professionals focused on advancing immuno-oncology therapeutics. SystImmune's approach combines traditional antibody discovery methods with computational design to develop targeted cancer treatments.
